Profile: Biogen Inc (BIIB.O)
20 Jan 2017
Biogen Inc., formerly Biogen Idec Inc., incorporated on April 1, 1997, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. The Company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies.
The Company offers TECFIDERA and PLEGRIDY to treat relapsing forms of MS in the United States, and to treat relapsing-remitting MS (RRMS) in the European Union. It offers AVONEX to treat relapsing forms of MS. The Company provides TYSABRI to treat relapsing forms of MS, and Crohn's disease in the United States. It offers FAMPYRA to treat walking ability for patients with MS. The Company offers ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes. It provides ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes. In addition, the Company is also engaged in developing late stage product candidates, including ZINBRYTA, a monoclonal antibody for the treatment of RRMS; Aducanumab (BIIB037), for the treatment of Neurodegeneration, and Nusinersen for other programs.
The Company competes with Teva Pharmaceuticals Industries Ltd., Novartis AG, Merck KGaA, Pfizer Inc., Bayer Group, Sanofi, Baxalta, CSL Behring and Emergent Biosolutions.
225 Binney St
CAMBRIDGE MA 02142-1031
Company Web Links
- Biogen to pay Forward Pharma $1.25 bln to protect MS drug
- Biogen to pay Forward Pharma $1.25 billion to protect MS drug
- UPDATE 2-Biogen to pay Forward Pharma $1.25 bln to protect MS drug
- BRIEF-FORWARD PHARMA AGREES TO ENTER INTO SETTLEMENT AND LICENSE AGREEMENT WITH BIOGEN
- Biogen in $1.25 bln deal with Forward Pharma to protect MS drug